BioLineRx (NASDAQ:BLRX) Share Price Crosses Above Two Hundred Day Moving Average – Should You Sell?

BioLineRx Ltd. (NASDAQ:BLRX)’s share price passed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $2.88 and traded as high as $3.29. BioLineRx shares last traded at $3.28, with a volume of 4,860 shares changing hands.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of BioLineRx in a report on Monday, April 20th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, BioLineRx presently has a consensus rating of “Hold”.

BioLineRx Trading Up 2.2%

The business’s fifty day moving average is $2.79 and its 200-day moving average is $2.88. The stock has a market capitalization of $14.33 million, a PE ratio of -1.71 and a beta of 1.53. The company has a quick ratio of 1.43, a current ratio of 1.58 and a debt-to-equity ratio of 0.16.

BioLineRx (NASDAQ:BLRX) last released its earnings results on Wednesday, May 27th. The biotechnology company reported ($0.36) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.04) by $0.68. BioLineRx had a negative net margin of 563.70% and a negative return on equity of 37.73%. The firm had revenue of $0.48 million during the quarter, compared to the consensus estimate of $0.34 million.

BioLineRx Company Profile

BioLineRx (NASDAQ: BLRX) is a clinical-stage biopharmaceutical company that discovers and develops novel small-molecule therapies to address unmet medical needs. The company focuses on identifying promising drug candidates through licensing and collaboration agreements with academic institutions and biotech innovators, then advancing these candidates through preclinical and clinical development stages. BioLineRx’s pipeline spans oncology, immunology and inflammatory diseases, central nervous system disorders and pain management.

Among its clinical programs, BioLineRx is advancing targeted cancer therapies designed to improve outcomes for patients with difficult-to-treat tumors.